Tamibarotene: Completed Phase IIb enrollment

CytRx completed enrollment of 140 patients with stage IIIb or IV NSCLC who had not received prior non-adjuvant chemotherapy in a double-blind, international Phase IIb trial comparing 6 mg/m 2 oral tamibarotene plus paclitaxel and carboplatin vs. placebo plus paclitaxel and carboplatin for up to 6 cycles. In January, an independent DSMB recommended completion of the trial. ...